1Hillmen P, Lewis SM, Bessler M, et al. Natural history of paroxysmal nocturnal hemoglobinuria[J]. N Engl J Med, 1995, 333(19): 1253-1258.
2Rosse WF. Paroxysmal nocturnal hemoglobinuria as a molecular disease[J]. Medicine (Baltimore), 1997, 76(2): 63-93.
3Luzzatto L. Paroxysmal nocturnal hemoglobinuria: an acquired X-linked genetic disease with somatic-ceU mosaicism[J]. Curr Opin Genet Dev, 2006, 16(3): 317-322.
4Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria[J], Cell, 1993, 73(4): 703-711.
5Bessler M, Mason P J, Hillmen P, et al. Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene[J]. EMBO J, 1994, 13(1): 110-117.
6Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria[J]. Lancet, 2009, 373(9665): 759-767.
7Rother RP, Rollins SA, Mojcik CF, et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria[J]. Nat Biotechnol, 2007, 25(11): 1256-1264.
8Dmytrijuk A, Robie-Suh K, Cohen MH, et al. FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria[J]. Oncologist, 2008, 13(9): 993-1000.
9Alexion Pharmaceuticals. Inc. Solaris (eculizumab) prescribing information[EB/OL]. (2012-12-01)[2014-01-01]. http://www.soliris. net/sites/default/files/assets/soliris_pi.pdf.
10Hill A, Hillmen P, Richards S J, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria[J]. Blood, 2005, 106(7): 2559-2565.
